Services >> Preclinical >> Cardiovascular

Cardiovascular services to evaluate preclinical safety and efficacy

Sidebar Image
undefined

Cardiovascular disease (CVD) is one of the leading causes of death for both men and women worldwide. CVDs affect the heart and blood vessels, leading to a variety of conditions including ischemia, stroke, heart attack, angina and cardiomyopathy. Eurofins, through the expertise of Panlabs, has been conducting in vivo testing for cardiovascular disease using in vivo models for both side-effect profiling and efficacy for over 25 years.

Our staff, with their vast experience, is dedicated in assisting you to properly evaluate your lead series and clinical candidates. We offer a number of relevant cardiovascular disease models, including models of hypertension, thrombosis and arrhythmia. We can also provide many related ancillary services such as measuring relevant cytokine biomarkers in plasma though our highly sensitive ImmunoSignal™ services, measure lipids or perform blood chemistries.

Whether you are trying to evaluate potential cardiovascular liabilities during lead optimization or trying to verify in vivo efficacy, Eurofins can provide you high quality and reproducible results to progress your drug discovery program.

Advantages of Eurofins' cardiovascular in vivo studies:

  • Over 30 cardiovascular disease/dysfunction assays available
    • Hypertension
    • Ischemia-reperfusion injury
    • Dyslipidemia
    • Arrhythmia and QT interval
    • Thrombosis
    • Adrenergic mediators
    • Clotting homeostasis
    • General cardiovascular safety assessment
  • Experienced in combination studies with standard of care control regimes
  • Models are qualified in a dose-dependent manner with approved benchmark positive controls
  • Companion services can monitor blood and organ exposure and biomarker analysis for PK/PD assessment
  • Ancillary services: clinical chemistry, lipid profiles, hematology and blood gases.